Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass... It is being developed jointly by PeriCor and Schering-Plough.
- Mechanism
- Curator reviewed
The mechanism by which acadesine selectively kills B-cells is not yet fully elucidated. The action of acadesine does not require the tumour suppressor protein p53 like other treatments. This is important, as p53 is often missing or defective in cancerous B-cells. Studies have shown acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes.
- Primary indication
- Investigated for use/treatment in cardiac reperfusion injury, cardiovascular disorders, and coronary artery disease.Curator reviewed
- Formula / weight
- C9H14N4O5 · 258.2313 g/mol (avg)
- Also known as
- AICA-riboside
- Code names
- GP 1-110
Resolves to
RTRQQBHATOEIAF-UUOKFMHZSA-NSMILES[H][C@]1(CO)O[C@]([H])([C@H](O)[C@@H]1O)N1C=NC(C(N)=O)=C1NWhat you can answer from here — as of January 29, 2025
Which drugs share a target with Acadesine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account